The table below shows CRISPR Therapeutics AG's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$345.01M
-$142.77M
-$260.38M
-$495.74M
$538.97M
-$238.37M
Capital expenditure
$914.00K
$1.90M
$9.47M
$37.19M
$81.70M
$18.36M
Investing cash flow
-$31.80M
-$280.48M
$374.65M
-$258.65M
-$1.04B
-$541.17M
Dividends paid
-
-
-
-
CRSP operating cash flow (10-K history)
CRISPR Therapeutics AG reported operating cash flow of -$345.01M for fiscal year 2025. That is down 141.7% from -$142.77M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$52.86M (FY 2016) to -$345.01M. Figures come from the company's audited annual reports as filed with the SEC.
